CRISPR Therapeutics AG (CRSP) Income from Continuing Operations (2015 - 2026)

CRISPR Therapeutics AG has disclosed Income from Continuing Operations across 12 years of filings, most recently posting 122931000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 122931000.0, up 9.61% year-over-year; the trailing twelve-month figure through Mar 2026 was 41930000.0 (up 136.64% YoY), and the FY2025 annual result was 28893000.0, down 22.25% from the prior year.
• Income from Continuing Operations came in at 122931000.0 for Q1 2026 at CRISPR Therapeutics AG, down from 479859000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 479859000.0 in Q4 2025 to a low of 208557000.0 in Q2 2025.
• The 5-year median for Income from Continuing Operations is 112152000.0 (2023), against an average of 50649117.65.
• Across the five-year window, Income from Continuing Operations sank 124.47% in 2022 and soared 311.71% in 2024, its largest moves.
• CRISPR Therapeutics AG's Income from Continuing Operations stood at 110526000.0 in 2022, then soared by 180.45% to 88923000.0 in 2023, then jumped by 311.71% to 366102000.0 in 2024, then surged by 31.07% to 479859000.0 in 2025, then tumbled by 125.62% to 122931000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 122931000.0 (Q1 2026), 479859000.0 (Q4 2025), and 106441000.0 (Q3 2025), per Business Quant data.